Sinovac Biotech Ltd. Aktie News

PEKING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) („SINOVAC“ oder das „Unternehmen“), ein führender Anbieter biopharmazeutischer Produkte in China, gab heute bekannt, dass es seine ungeprüften Finanzergebnisse für die sechs Monate zum 30. Juni 2026 bei der US-Börsenaufsicht eingereicht hat. Eine elektronische Kopie der Finanzergebnisse ist auf der Website des Unternehmens unter www.si...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) („SINOVAC“ oder „das Unternehmen“), ein führender Anbieter biopharmazeutischer Produkte in China, gab heute bekannt, dass die Frist für Aktionäre und Nominee-Broker zur Einreichung von Zahlungsanweisungen im Zusammenhang mit der zuvor angekündigten Sonder-Bar-Dividende des Unternehmens verlängert wurde. Das Unternehmen hatte zuvor ein...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed at the Company's we...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and i...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company's previously declared special cash dividend. The Company previously announced a special cash dividend of ...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2025. First Half of 2025 Financial Summary Sales for the six months ended June 30, 2025 were $130.3 million, compared to $128.7 million in the prior year period. The...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SIN...